tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Doi R et al. Biochemical characterization of the effects of FK506 on signal transduction in exocytotic function of rat pancreatic acini. 1993 J. Pharmacol. Exp. Ther. pmid:7679738
Cavaillé-Coll M and Mielach FA Choice of cyclophosphamide dose in baboon-to-human liver transplantation. 1993 Lancet pmid:7679768
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Gregory CR et al. Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. 1993 Transplant. Proc. pmid:7679842
Zeevi A et al. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. 1993 Transplant. Proc. pmid:7679843
Inoue T et al. Isolation of mitochondrial cyclophilin from bovine heart. 1993 Biochem. Biophys. Res. Commun. pmid:7679902
Nishinaka Y et al. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. 1993 J. Cardiovasc. Pharmacol. pmid:7681507
Luan S et al. Immunosuppressants implicate protein phosphatase regulation of K+ channels in guard cells. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7681590
Doi R et al. Structural and functional changes of exocrine pancreas induced by FK506 in rats. 1993 Gastroenterology pmid:7681795
Rotonda J et al. Improved calcineurin inhibition by yeast FKBP12-drug complexes. Crystallographic and functional analysis. 1993 J. Biol. Chem. pmid:7681823
Lieberman I et al. Synergy between tetrandrine and FK506 in prevention of diabetes in BB rats. 1993 Life Sci. pmid:7504774
Xu RX et al. 1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin. 1993 Biopolymers pmid:7682113
Müller MK et al. [Pathophysiologic concepts and protective possibilities in experimental pancreatic lesions]. 1993 Z Gastroenterol pmid:7504856
Panis Y and Valleur P [Small intestine transplantation. Experimental and clinical results]. 1993 Ann Chir pmid:7504899
Tsai M et al. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. 1993 Eur. J. Immunol. pmid:7504992
Hendrickson BA et al. Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. 1993 Gene pmid:7505249
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
McDiarmid SV et al. FK506 conversion for intractable rejection of the liver allograft. 1993 Transpl. Int. pmid:7507675
Tokunaga Y et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. 1993 Transpl. Int. pmid:7507676
Winkler M et al. Conversion from cyclosporin to FK 506 after liver transplantation. 1993 Transpl. Int. pmid:7507677
Kadmon M et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. 1993 Gastroenterology pmid:7683296
Denesyuk AI et al. Structural similarity of the binding sites of cyclophilin A-cyclosporin A and FKBP-FK506 systems. 1993 Biochem. Biophys. Res. Commun. pmid:7683466
Waschulewski IH et al. Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. 1993 Br. J. Pharmacol. pmid:7683567
Morikawa K et al. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. 1993 Antimicrob. Agents Chemother. pmid:7509146
Schwaninger M et al. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP-responsive element in a nonimmune cell line. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7509460
Ohtake M et al. Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506. 1993 Gastroenterol. Jpn. pmid:7683616
Ohnishi H et al. Natural killer cell may impair liver regeneration in fulminant hepatic failure. 1993 Gastroenterol. Jpn. pmid:7683619
Natazuka T et al. FK506 and cyclosporin a regulate proliferation and proto-oncogene expression in HTLV-1-associated myelopathy/tropical-spastic-paraparesis-derived T cells. 1993 Int. J. Cancer pmid:7683633
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Li W and Handschumacher RE Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. 1993 J. Biol. Chem. pmid:7686148
Wong PY et al. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. 1993 J. Hepatol. pmid:7686192
Sakr MF et al. FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. 1993 J. Hepatol. pmid:7686193
Calne RY et al. Intestinal transplant for recurring mesenteric desmoid tumour. 1993 Lancet pmid:7686241
Jacobs JC et al. Pyoderma gangrenosum in infancy. 1993 J. Am. Acad. Dermatol. pmid:7688775
Garrity GM et al. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and rapamycin. 1993 J. Ind. Microbiol. pmid:7688970
Hoof T et al. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent rapamycin. 1993 Eur. J. Pharmacol. pmid:7689059
Jin YJ and Burakoff SJ The 25-kDa FK506-binding protein is localized in the nucleus and associates with casein kinase II and nucleolin. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7689229
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Lieberman R FK506, artificial intelligence and pharmacoeconomics. 1993 J Clin Pharmacol pmid:7690045
McMichael J et al. An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. 1993 J Clin Pharmacol pmid:7690046
Jain AB et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. 1993 J Clin Pharmacol pmid:7690047
Cheng JW et al. 15N NMR relaxation studies of the FK506 binding protein: backbone dynamics of the uncomplexed receptor. 1993 Biochemistry pmid:7690248
Hacker J and Fischer G Immunophilins: structure-function relationship and possible role in microbial pathogenicity. 1993 Mol. Microbiol. pmid:7526121
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Uemoto S et al. Experience with FK506 in living-related liver transplantation. 1993 Transplantation pmid:7679528
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531